Cart
sales@molnova.com
Rilotumumab
CAS No. 872514-65-3
Rilotumumab( —— )
Catalog No. M36702 CAS No. 872514-65-3
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 635 | In Stock |
|
| 10MG | 1017 | In Stock |
|
| 25MG | 1501 | In Stock |
|
| 50MG | 1981 | In Stock |
|
| 100MG | 2678 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRilotumumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionRilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling.
-
DescriptionRilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.
-
In VitroRilotumumab (10 μg/mL; overnight) shows the decrease of MET phosphorylation at Y1234 and Y1235, and an increase in total MET.Western Blot Analysis Cell Line:U87MG.vIII cells Concentration:10 μg/mL Incubation Time:Overnight Result:Showed MET phosphorylation at tyrosine residue 1234 (Y1234) and Y1235 ~50% lower in U87MG.vIII cells than in untreated cells.Showed an increase in total MET compared with untreated cells.
-
In VivoRilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo.Animal Model:6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells Dosage:1.5 mg/kg Administration: Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days Result:Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorc-Met/HGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number872514-65-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24.?
molnova catalog
related products
-
Capmatinib hydrochlo...
Capmatinib hydrochloride is a potent orally active selective and ATP competitive c-Met kinase inhibitor?potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).
-
PF-04217903
PF-04217903 is a potent, selective, ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM.
-
TRX818
TRX-818 is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities.
